<!DOCTYPE html><html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>Module 5: Metabolic & Electrolyte Emergencies</title> <style> /* Main Styles from Previous Document - EXACT MATCH */ body { font-family: 'Calibri', 'Segoe UI', sans-serif; line-height: 1.5; color: #2c3e50; margin: 2cm; background-color: #ffffff; counter-reset: chapter section figure table; }
<!DOCTYPE html><html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>Module 5: Metabolic & Electrolyte Emergencies</title> <style> /* Main Styles from Previous Document - EXACT MATCH */ body { font-family: 'Calibri', 'Segoe UI', sans-serif; line-height: 1.5; color: #2c3e50; margin: 2cm; background-color: #ffffff; counter-reset: chapter section figure table; }
        h1 {
        font-size: 28pt;
        font-weight: bold;
        color: #1a5276;
        text-align: center;
        border-bottom: 3px double #3498db;
        padding-bottom: 10px;
        margin-bottom: 30px;
    }
    
    h2 {
        font-size: 18pt;
        font-weight: bold;
        color: #ffffff;
        background-color: #2980b9;
        padding: 10px 15px;
        border-radius: 5px;
        margin-top: 30px;
        page-break-after: avoid;
    }
    
    h3 {
        font-size: 14pt;
        font-weight: bold;
        color: #154360;
        margin-top: 20px;
        margin-bottom: 10px;
        page-break-after: avoid;
    }
    
    h4 {
        font-size: 12.5pt;
        font-weight: bold;
        color: #21618c;
        margin-top: 15px;
        margin-bottom: 8px;
    }
    
    .module-title {
        font-size: 20pt;
        font-weight: bold;
        color: #21618c;
        margin-top: 40px;
        border-left: 6px solid #3498db;
        padding-left: 15px;
    }
    
    .chapter-number {
        background-color: #3498db;
        color: white;
        padding: 5px 12px;
        border-radius: 50%;
        display: inline-block;
        margin-right: 10px;
        font-weight: bold;
    }
    
    /* Lists */
    ul, ol {
        padding-left: 1.5em;
        margin-bottom: 1em;
    }
    
    li {
        margin-bottom: 8px;
        font-size: 11.5pt;
    }
    
    .sub-list {
        list-style-type: lower-alpha;
        padding-left: 2.5em;
    }
    
    .drug-list {
        columns: 2;
        column-gap: 50px;
        margin-top: 15px;
    }
    
    .drug-list li {
        break-inside: avoid;
    }
    
    /* Special Boxes - EXACT MATCH */
    .study-format {
        background-color: #e8f4fc;
        border: 1px solid #aed6f1;
        border-left: 6px solid #2e86c1;
        padding: 20px;
        margin-top: 30px;
        page-break-inside: avoid;
    }
    
    .clinical-pearl {
        background-color: #fff3cd;
        border: 1px solid #ffeaa7;
        border-left: 6px solid #fdcb6e;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    .warning-box {
        background-color: #f8d7da;
        border: 1px solid #f5c6cb;
        border-left: 6px solid #e74c3c;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    .definition-box {
        background-color: #d1ecf1;
        border: 1px solid #bee5eb;
        border-left: 6px solid #17a2b8;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    /* Tables - EXACT MATCH */
    .comparison-table {
        width: 100%;
        border-collapse: collapse;
        margin: 20px 0;
        font-size: 11pt;
    }
    
    .comparison-table th {
        background-color: #2980b9;
        color: white;
        padding: 10px;
        text-align: left;
        border: 1px solid #1a5276;
    }
    
    .comparison-table td {
        padding: 10px;
        border: 1px solid #ddd;
        vertical-align: top;
    }
    
    .comparison-table tr:nth-child(even) {
        background-color: #f8f9fa;
    }
    
    /* Figures and Captions - EXACT MATCH */
    .figure {
        text-align: center;
        margin: 20px 0;
        page-break-inside: avoid;
    }
    
    .figure img {
        max-width: 100%;
        height: auto;
    }
    
    .caption {
        font-style: italic;
        font-size: 10.5pt;
        color: #666;
        margin-top: 5px;
        text-align: center;
    }
    
    /* Page Layout - EXACT MATCH */
    .page-break {
        page-break-before: always;
    }
    
    .footer-note {
        font-size: 9pt;
        color: #7f8c8d;
        text-align: center;
        margin-top: 30px;
        border-top: 1px solid #ecf0f1;
        padding-top: 10px;
    }
    
    /* Drug Template - EXACT MATCH */
    .drug-template {
        background-color: #f9f9f9;
        border: 1px solid #ddd;
        padding: 20px;
        margin: 25px 0;
        border-radius: 5px;
        page-break-inside: avoid;
    }
    
    .drug-template h4 {
        color: #2c3e50;
        border-bottom: 2px solid #3498db;
        padding-bottom: 5px;
        margin-top: 0;
    }
    
    .template-section {
        margin-bottom: 15px;
    }
    
    .template-label {
        font-weight: bold;
        color: #2980b9;
        display: inline-block;
        width: 180px;
    }
    
    /* Emoji Styling - EXACT MATCH */
    .emoji {
        font-size: 1.2em;
    }
    
    /* Print Specific - EXACT MATCH */
    @media print {
        body {
            margin: 1.5cm;
            font-size: 11pt;
        }
        
        .page-break {
            page-break-before: always;
        }
        
        .no-print {
            display: none;
        }
        
        a {
            color: black;
            text-decoration: none;
        }
    }
    
    /* Learning Objectives - EXACT MATCH */
    .learning-objectives {
        background-color: #e8f6f3;
        border: 1px solid #a2d9ce;
        padding: 15px;
        margin: 20px 0;
        border-radius: 5px;
    }
    
    .objective-list {
        list-style-type: none;
        padding-left: 0;
    }
    
    .objective-list li:before {
        content: "‚úì ";
        color: #27ae60;
        font-weight: bold;
        margin-right: 10px;
    }
    
    /* Additional Styles for Module 5 */
    .metabolic-box {
        background-color: #e8f8f5;
        border: 2px solid #45b39d;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
    }
    
    .dka-alert {
        background-color: #fdebd0;
        border: 2px solid #f39c12;
        color: #d35400;
        padding: 15px;
        margin: 20px 0;
        font-weight: bold;
        border-radius: 5px;
        text-align: center;
    }
    
    .hyperkalemia-box {
        background-color: #f2d7d5;
        border: 2px solid #c0392b;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
        font-weight: bold;
    }
    
    .hypoglycemia-box {
        background-color: #fef9e7;
        border: 2px solid #f1c40f;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
    }
    
    .acidosis-box {
        background-color: #d5f4e6;
        border: 2px solid #27ae60;
        padding: 15px;
        margin: 15px 0;
        border-radius: 5px;
    }
    
    .calculation-box {
        background-color: #f4ecf7;
        border: 2px solid #8e44ad;
        padding: 15px;
        margin: 15px 0;
        border-radius: 5px;
        font-family: 'Courier New', monospace;
        font-size: 11pt;
    }
    
    /* Module 5 Specific Colors */
    .glucose-orange {
        color: #e67e22;
        font-weight: bold;
    }
    
    .insulin-blue {
        color: #2980b9;
        font-weight: bold;
    }
    
    .calcium-green {
        color: #27ae60;
        font-weight: bold;
    }
    
    .potassium-red {
        color: #c0392b;
        font-weight: bold;
    }
    
    .bicarbonate-purple {
        color: #8e44ad;
        font-weight: bold;
    }
    
    .magnesium-teal {
        color: #17a2b8;
        font-weight: bold;
    }
</style>
</head> <body>
<div class="module-title">
    <span class="emoji">üü¶</span> MODULE 5: METABOLIC & ELECTROLYTE EMERGENCIES
    <div style="font-size: 12pt; font-weight: normal; font-style: italic; color: #7f8c8d;">
        (Hypoglycemia, Hyperkalemia, DKA, Severe Acidosis)
    </div>
</div>

<div class="learning-objectives">
    <h3 style="color: #148f77; margin-top: 0;">üìñ Learning Objectives</h3>
    <ul class="objective-list">
        <li>Master the management of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)</li>
        <li>Understand emergency management of hyperkalemia (life-threatening arrhythmias)</li>
        <li>Learn appropriate glucose administration for hypoglycemia (10%, 25%, 50% dextrose)</li>
        <li>Differentiate between calcium gluconate and calcium chloride</li>
        <li>Manage severe metabolic acidosis (when and how to use bicarbonate)</li>
        <li>Understand insulin protocols for hyperkalemia and DKA</li>
        <li>Recognize and treat hypocalcemia and hypomagnesemia emergencies</li>
        <li>Apply knowledge to clinical scenarios and exam questions</li>
    </ul>
</div>

<!-- INTRODUCTION -->
<h2><span class="chapter-number">0</span> Introduction: The Body's Chemistry Set</h2>

<div class="warning-box">
    <strong>‚ö†Ô∏è METABOLIC EMERGENCES KILL QUIETLY:</strong> A potassium of 7.0 mEq/L can cause cardiac arrest without warning. A pH of 6.9 can stop enzyme function. A glucose of 1.5 mmol/L can cause irreversible brain damage. Monitor, interpret, and act.
</div>

<div class="clinical-pearl">
    <strong>üß† Core Concept:</strong> Metabolic emergencies involve imbalances in:<br>
    1. <strong class="glucose-orange">Energy</strong> (glucose - too high or too low)<br>
    2. <strong class="potassium-red">Electrical stability</strong> (potassium, calcium, magnesium)<br>
    3. <strong class="bicarbonate-purple">Acid-base balance</strong> (pH, bicarbonate)<br>
    Each requires specific correction strategies to avoid complications.
</div>

<!-- CHAPTER 1: DKA VS HHS MANAGEMENT -->
<h2><span class="chapter-number">1</span> Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS)</h2>

<div class="definition-box">
    <strong>DKA:</strong> Hyperglycemia (blood glucose >13.9 mmol/L or 250 mg/dL), metabolic acidosis (pH <7.3, bicarbonate <15 mEq/L), ketonemia/ketonuria. Caused by absolute or relative insulin deficiency.<br><br>
    <strong>HHS:</strong> Extreme hyperglycemia (blood glucose >33.3 mmol/L or 600 mg/dL), hyperosmolality (>320 mOsm/kg), absence of significant ketosis. Usually slower onset than DKA.
</div>

<h3>1.1 DKA vs HHS Comparison</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 20%;">Parameter</th>
            <th>Diabetic Ketoacidosis (DKA)</th>
            <th>Hyperosmolar Hyperglycemic State (HHS)</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Typical patient</strong></td>
            <td>Type 1 DM, younger</td>
            <td>Type 2 DM, elderly</td>
        </tr>
        <tr>
            <td><strong>Onset</strong></td>
            <td>Hours to 1-2 days</td>
            <td>Days to weeks</td>
        </tr>
        <tr>
            <td><strong>Blood glucose</strong></td>
            <td>>13.9 mmol/L (250 mg/dL)</td>
            <td>>33.3 mmol/L (600 mg/dL), often >55.5 mmol/L (1000 mg/dL)</td>
        </tr>
        <tr>
            <td><strong>pH</strong></td>
            <td><7.3 (often <7.0 in severe cases)</td>
            <td>>7.3 (usually normal or mild acidosis)</td>
        </tr>
        <tr>
            <td><strong>Bicarbonate</strong></td>
            <td><15 mEq/L</td>
            <td>>15 mEq/L</td>
        </tr>
        <tr>
            <td><strong>Ketones</strong></td>
            <td>Large in urine and serum</td>
            <td>Small or absent</td>
        </tr>
        <tr>
            <td><strong>Osmolality</strong></td>
            <td>Variable, usually <320 mOsm/kg</td>
            <td>>320 mOsm/kg (often >350)</td>
        </tr>
        <tr>
            <td><strong>Mental status</strong></td>
            <td>Alert to comatose</td>
            <td>More likely comatose (25-50%)</td>
        </tr>
        <tr>
            <td><strong>Mortality</strong></td>
            <td>1-5%</td>
            <td>10-20% (higher due to age/comorbidities)</td>
        </tr>
    </tbody>
</table>

<h3>1.2 DKA Management Protocol</h3>

<div class="dka-alert">
    <strong>üíâ DKA MANAGEMENT PROTOCOL (ABCDEFG):</strong><br>
    <br>
    <strong>A - Assessment & Access:</strong><br>
    ‚Ä¢ IV access x2 (large bore)<br>
    ‚Ä¢ Bloods: Glucose, electrolytes, VBG/ABG, ketones, renal function<br>
    ‚Ä¢ ECG (check for hyperkalemia changes)<br>
    ‚Ä¢ Urine dipstick (glucose, ketones)<br>
    <br>
    <strong>B - Begin Fluids:</strong><br>
    ‚Ä¢ 1-2 L NS over 1-2 hours (15-20 mL/kg)<br>
    ‚Ä¢ Then switch to 0.45% NaCl or NS based on sodium<br>
    ‚Ä¢ Maintain urine output >0.5 mL/kg/hr<br>
    <br>
    <strong>C - Continuous Insulin:</strong><br>
    ‚Ä¢ Bolus: 0.1 units/kg IV<br>
    ‚Ä¢ Infusion: 0.1 units/kg/hr (mix 50 units in 50 mL NS = 1 unit/mL)<br>
    ‚Ä¢ Target glucose drop: 2.8-4.2 mmol/L/hr (50-75 mg/dL/hr)<br>
    <br>
    <strong>D - Dextrose when needed:</strong><br>
    ‚Ä¢ Add D5W when glucose <14 mmol/L (250 mg/dL)<br>
    ‚Ä¢ Continue insulin until anion gap closed, ketones cleared<br>
    <br>
    <strong>E - Electrolytes (especially K‚Å∫):</strong><br>
    ‚Ä¢ K‚Å∫ often high initially but total body K‚Å∫ depleted<br>
    ‚Ä¢ Add K‚Å∫ to fluids when: K‚Å∫ <5.5 mEq/L and urine output adequate<br>
    ‚Ä¢ Usually 20-40 mEq K‚Å∫/L at 10-20 mEq/hr<br>
    <br>
    <strong>F - Find & Fix precipitant:</strong><br>
    ‚Ä¢ Infection (chest, urine, skin)<br>
    ‚Ä¢ Myocardial infarction<br>
    ‚Ä¢ Non-compliance with insulin<br>
    ‚Ä¢ New-onset diabetes<br>
    <br>
    <strong>G - Glucose monitoring:</strong><br>
    ‚Ä¢ Hourly glucose checks<br>
    ‚Ä¢ Monitor electrolytes every 2-4 hours<br>
    ‚Ä¢ Transition to SC insulin when eating, gap closed
</div>

<!-- CHAPTER 2: DRUG 1 - DEXTROSE (10%, 25%, 50%) -->
<div class="page-break"></div>
<h2><span class="chapter-number">2</span> Core Drug 1: Dextrose (10%, 25%, 50%)</h2>

<div class="drug-template">
    <h4>DEXTROSE - RAPID CORRECTION OF HYPOGLYCEMIA</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Carbohydrate, monosaccharide
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Provides immediate source of glucose for cellular metabolism<br>
        ‚Ä¢ Reverses neuroglycopenia (brain glucose deprivation)<br>
        ‚Ä¢ Stimulates endogenous insulin secretion (in non-diabetics)<br>
        ‚Ä¢ Osmotic agent - draws water into vascular space<br>
        ‚Ä¢ 50% dextrose is hypertonic (2525 mOsm/L) - significant fluid shift
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Hypoglycemia (blood glucose <4.0 mmol/L or 72 mg/dL)<br>
        ‚Ä¢ Symptomatic hypoglycemia regardless of reading<br>
        ‚Ä¢ Hyperkalemia (adjunct with insulin - drives K‚Å∫ into cells)<br>
        ‚Ä¢ Alcohol intoxication (provides glucose for metabolism)<br>
        ‚Ä¢ Insulin overdose treatment<br>
        ‚Ä¢ Pre-hospital management of altered mental status (if hypoglycemia suspected)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Intracranial or intraspinal hemorrhage (relative - hypertonic solution)<br>
        ‚Ä¢ Diabetic ketoacidosis or HHS (unless hypoglycemic)<br>
        ‚Ä¢ Hypersensitivity to corn products (some preparations)<br>
        ‚Ä¢ Anuria, oliguria (relative - fluid overload risk)<br>
        ‚Ä¢ Delirium tremens (may worsen - give thiamine first)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="glucose-orange">Mild hypoglycemia (alert):</strong> 15-20g PO (4 glucose tablets, 120-180 mL juice)<br>
        ‚Ä¢ <strong class="glucose-orange">Severe hypoglycemia (altered):</strong> 25g IV (50 mL of 50% or 250 mL of 10%)<br>
        ‚Ä¢ <strong class="glucose-orange">Refractory hypoglycemia:</strong> Repeat 25g IV, then start 10% dextrose infusion<br>
        ‚Ä¢ <strong class="glucose-orange">Infusion:</strong> D5W at 100 mL/hr (5g glucose/hour) or D10W at 50-100 mL/hr<br>
        ‚Ä¢ <strong class="glucose-orange">For hyperkalemia:</strong> 25g dextrose (50 mL 50%) with 10 units regular insulin IV
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="glucose-orange">Neonates:</strong> 2 mL/kg of 10% dextrose (200 mg/kg)<br>
        ‚Ä¢ <strong class="glucose-orange">Infants/children:</strong> 0.5-1 g/kg (2-4 mL/kg of 25% OR 5-10 mL/kg of 10%)<br>
        ‚Ä¢ <strong class="glucose-orange">Adolescents:</strong> 25g IV (as adult)<br>
        ‚Ä¢ <strong class="glucose-orange">Infusion:</strong> D10W at maintenance rate (varies by weight)<br>
        ‚Ä¢ <strong class="glucose-orange">MAX concentration for peripheral IV:</strong> 12.5% (higher risks phlebitis)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="glucose-orange">Routes:</strong> IV (emergencies), PO (if alert), buccal gel<br>
        ‚Ä¢ <strong class="glucose-orange">Concentrations:</strong> 5% (D5W), 10% (D10W), 25%, 50%<br>
        ‚Ä¢ <strong class="glucose-orange">For IV push:</strong> Use 50% dextrose (25g/50mL) - give over 1-3 minutes<br>
        ‚Ä¢ <strong class="glucose-orange">Peripheral IV caution:</strong> 50% dextrose is VERY hypertonic - ensure IV patency<br>
        ‚Ä¢ <strong class="glucose-orange">Extravasation:</strong> Causes tissue necrosis - use large vein, check placement<br>
        ‚Ä¢ <strong class="glucose-orange">Buccal gel:</strong> 15g/30g tubes (GlucoGel¬Æ, DextroGel¬Æ) - rub on gums
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Hyperglycemia (rebound)<br>
        ‚Ä¢ Fluid overload (especially with large volumes)<br>
        ‚Ä¢ Hypokalemia (insulin-mediated shift)<br>
        ‚Ä¢ Local irritation/phlebitis<br>
        ‚Ä¢ Pain at injection site (hypertonic solution)<br>
        ‚Ä¢ Burning with buccal administration
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Wernicke's encephalopathy (in thiamine-deficient patients)<br>
        ‚Ä¢ Cerebral edema (especially in children with rapid correction)<br>
        ‚Ä¢ Tissue necrosis with extravasation (50% dextrose)<br>
        ‚Ä¢ Hyperosmolar coma (if given to hyperglycemic patient)<br>
        ‚Ä¢ Hypokalemia-induced arrhythmias<br>
        ‚Ä¢ Pulmonary edema (fluid overload in cardiac patients)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="glucose-orange">Insulin:</strong> Antagonizes effect (obvious)<br>
        ‚Ä¢ <strong class="glucose-orange">Blood products:</strong> Causes hemolysis if given through same line<br>
        ‚Ä¢ <strong class="glucose-orange">Phenytoin:</strong> Incompatible - precipitates<br>
        ‚Ä¢ <strong class="glucose-orange">Many antibiotics:</strong> Check compatibility before Y-site administration<br>
        ‚Ä¢ <strong class="glucose-orange">Warfarin:</strong> Variable effect on INR
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="glucose-orange">"THIAMINE FIRST"</strong> in alcoholics/malnourished before dextrose (prevents Wernicke's)<br>
        ‚Ä¢ <strong class="glucose-orange">Check glucose</strong> 15 minutes after treatment - rebound hypoglycemia common<br>
        ‚Ä¢ <strong class="glucose-orange">Oral vs IV:</strong> 15g PO raises glucose by ~2.2 mmol/L (40 mg/dL) in 20 minutes<br>
        ‚Ä¢ <strong class="glucose-orange">50% dextrose:</strong> Raises glucose by ~4.2 mmol/L (75 mg/dL) per 25g in 5-10 minutes<br>
        ‚Ä¢ <strong class="glucose-orange">Children:</strong> Use 10% or 25% (not 50%) to reduce cerebral edema risk<br>
        ‚Ä¢ <strong class="glucose-orange">Sulfonylurea overdose:</strong> May need 10% dextrose infusion for 24-48 hours<br>
        ‚Ä¢ <strong class="glucose-orange">Glucagon alternative:</strong> 1mg IM if no IV access (works in 10-15 minutes)<br>
        ‚Ä¢ <strong class="glucose-orange">Storage:</strong> 50% dextrose crystallizes when cold - warm before use if crystals visible
    </div>
</div>

<div class="hypoglycemia-box">
    <strong>üç¨ HYPOGLYCEMIA MANAGEMENT:</strong><br>
    ‚Ä¢ <strong>Mild (alert):</strong> 15-20g fast-acting carbs ‚Üí Check in 15 min ‚Üí Repeat if <4.0 mmol/L ‚Üí Follow with complex carb<br>
    ‚Ä¢ <strong>Severe (altered):</strong> IV dextrose 25g OR Glucagon 1mg IM ‚Üí Check in 15 min ‚Üí Start 10% dextrose infusion if recurrent<br>
    ‚Ä¢ <strong>Refractory:</strong> Consider hydrocortisone 100mg IV, octreotide 50mcg SC (for sulfonylurea overdose)
</div>

<!-- CHAPTER 3: DRUG 2 - INSULIN (REGULAR - IV USE) -->
<div class="page-break"></div>
<h2><span class="chapter-number">3</span> Core Drug 2: Insulin (Regular - IV Use)</h2>

<div class="drug-template">
    <h4>INSULIN (REGULAR) - FOR DKA, HYPERKALEMIA, AND TIGHT CONTROL</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Pancreatic hormone, short-acting insulin
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Binds insulin receptors ‚Üí facilitates glucose uptake into cells (muscle, fat)<br>
        ‚Ä¢ Stimulates glycogen synthesis, inhibits glycogenolysis and gluconeogenesis<br>
        ‚Ä¢ Promotes potassium entry into cells (activates Na‚Å∫/K‚Å∫ ATPase)<br>
        ‚Ä¢ Inhibits lipolysis ‚Üí reduces ketone production in DKA<br>
        ‚Ä¢ IV regular insulin onset 10-30 minutes, peak 30-60 minutes, duration 4-6 hours
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Diabetic ketoacidosis (DKA)<br>
        ‚Ä¢ Hyperosmolar hyperglycemic state (HHS)<br>
        ‚Ä¢ Hyperkalemia (with dextrose unless hyperglycemic)<br>
        ‚Ä¢ Perioperative glycemic control<br>
        ‚Ä¢ Critical illness hyperglycemia<br>
        ‚Ä¢ Insulin tolerance test (diagnostic)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Hypoglycemia<br>
        ‚Ä¢ Hypokalemia (relative - correct K‚Å∫ >3.3 mEq/L first in DKA)<br>
        ‚Ä¢ Allergy to insulin (rare) or preservatives<br>
        ‚Ä¢ During MRI (some insulin pens contain metal)<br>
        ‚Ä¢ No absolute contraindications in DKA/HHS (life-saving)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="insulin-blue">DKA/HHS bolus:</strong> 0.1 units/kg IV (optional - many protocols skip bolus)<br>
        ‚Ä¢ <strong class="insulin-blue">DKA/HHS infusion:</strong> 0.1 units/kg/hr (mix 50 units in 50 mL NS = 1 unit/mL)<br>
        ‚Ä¢ <strong class="insulin-blue">Titration:</strong> Increase by 0.05 units/kg/hr if glucose not falling by 2.8-4.2 mmol/L/hr<br>
        ‚Ä¢ <strong class="insulin-blue">Hyperkalemia:</strong> 10 units regular insulin IV with 25g dextrose (50 mL 50%)<br>
        ‚Ä¢ <strong class="insulin-blue">Critical care infusion:</strong> 0.5-5 units/hr, titrate to glucose 6-10 mmol/L (110-180 mg/dL)<br>
        ‚Ä¢ <strong class="insulin-blue">Transition to SC:</strong> Give first SC dose 1-2 hours before stopping infusion
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="insulin-blue">DKA:</strong> 0.1 units/kg IV bolus, then 0.1 units/kg/hr infusion<br>
        ‚Ä¢ <strong class="insulin-blue">Hyperkalemia:</strong> 0.1 units/kg with 0.5-1 g/kg dextrose<br>
        ‚Ä¢ <strong class="insulin-blue">Neonates:</strong> Start 0.02-0.1 units/kg/hr, careful monitoring<br>
        ‚Ä¢ <strong class="insulin-blue">Children <5 years:</strong> Consider lower starting dose (0.05 units/kg/hr)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="insulin-blue">Routes:</strong> IV infusion (preferred for emergencies), IV bolus, SC, IM<br>
        ‚Ä¢ <strong class="insulin-blue">Preparation for infusion:</strong> 50 units regular insulin in 50 mL NS = 1 unit/mL<br>
        ‚Ä¢ <strong class="insulin-blue">Alternative:</strong> 100 units in 100 mL NS = 1 unit/mL<br>
        ‚Ä¢ <strong class="insulin-blue">Must use dedicated line</strong> (adsorbs to plastic tubing - flush 50 mL through first)<br>
        ‚Ä¢ <strong class="insulin-blue">Pump required</strong> - never gravity drip<br>
        ‚Ä¢ <strong class="insulin-blue">Adsorption loss:</strong> Up to 80% loss to tubing without priming - use albumin-containing solutions or flush tubing
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Hypoglycemia (most common)<br>
        ‚Ä¢ Hypokalemia (insulin drives K‚Å∫ into cells)<br>
        ‚Ä¢ Hypomagnesemia, hypophosphatemia<br>
        ‚Ä¢ Lipohypertrophy at injection sites (chronic use)<br>
        ‚Ä¢ Weight gain (chronic use)<br>
        ‚Ä¢ Local allergic reactions (rare with human insulin)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Severe hypoglycemia ‚Üí seizures, coma, death<br>
        ‚Ä¢ Cerebral edema (especially in children with DKA)<br>
        ‚Ä¢ Anaphylaxis (extremely rare with human insulin)<br>
        ‚Ä¢ Insulin antibodies with animal insulin (rare now)<br>
        ‚Ä¢ Diabetic retinopathy progression (with rapid glucose lowering)<br>
        ‚Ä¢ Hypokalemia-induced arrhythmias
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="insulin-blue">Beta-blockers:</strong> Mask hypoglycemia symptoms, impair recovery<br>
        ‚Ä¢ <strong class="insulin-blue">Corticosteroids, thiazides, niacin:</strong> Increase insulin requirements<br>
        ‚Ä¢ <strong class="insulin-blue">Alcohol, ACE inhibitors, MAOIs:</strong> Increase hypoglycemia risk<br>
        ‚Ä¢ <strong class="insulin-blue">Sympathomimetics (adrenaline):</strong> Increase insulin requirements<br>
        ‚Ä¢ <strong class="insulin-blue">Octreotide:</strong> Alters insulin requirements<br>
        ‚Ä¢ <strong class="insulin-blue">Many herbal supplements:</strong> Affect glucose control
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="insulin-blue">DKA:</strong> Continue insulin until anion gap closed (not until glucose normal)<br>
        ‚Ä¢ <strong class="insulin-blue">Glucose drop target:</strong> 2.8-4.2 mmol/L/hr (50-75 mg/dL/hr) - faster causes cerebral edema<br>
        ‚Ä¢ <strong class="insulin-blue">Potassium:</strong> Check K‚Å∫ every 2-4 hours, add to fluids when K‚Å∫ <5.5 mEq/L<br>
        ‚Ä¢ <strong class="insulin-blue">Hyperkalemia dose:</strong> Works in 15-30 minutes, lasts 4-6 hours<br>
        ‚Ä¢ <strong class="insulin-blue">Adsorption solution:</strong> Add 1 mL of patient's blood to bag OR use 0.1% albumin in NS<br>
        ‚Ä¢ <strong class="insulin-blue">Half-life:</strong> IV: 4-6 minutes (very short) - why continuous infusion needed<br>
        ‚Ä¢ <strong class="insulin-blue">SC overlap:</strong> Give first SC dose 1-2 hours before stopping IV to avoid rebound<br>
        ‚Ä¢ <strong class="insulin-blue">Monitoring:</strong> Hourly glucose, 2-4 hour electrolytes, VBG every 4 hours in DKA
    </div>
</div>

<!-- CHAPTER 4: DRUG 3 - CALCIUM GLUCONATE -->
<div class="page-break"></div>
<h2><span class="chapter-number">4</span> Core Drug 3: Calcium Gluconate</h2>

<div class="drug-template">
    <h4>CALCIUM GLUCONATE - FIRST-LINE FOR HYPERKALEMIA</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Electrolyte supplement, cation
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Raises extracellular calcium ‚Üí increases myocardial action potential threshold<br>
        ‚Ä¢ Stabilizes cardiac membrane ‚Üí protects against hyperkalemia-induced arrhythmias<br>
        ‚Ä¢ Does NOT lower serum potassium (only protects heart)<br>
        ‚Ä¢ Provides calcium for neuromuscular function, coagulation, bone<br>
        ‚Ä¢ Gluconate salt contains 9% elemental calcium (vs 27% in chloride)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ <strong class="calcium-green">Hyperkalemia with ECG changes</strong> (first-line treatment)<br>
        ‚Ä¢ Hypocalcemia (symptomatic or ionized calcium <0.8 mmol/L)<br>
        ‚Ä¢ Calcium channel blocker overdose<br>
        ‚Ä¢ Magnesium toxicity (antagonizes neuromuscular effects)<br>
        ‚Ä¢ Hydrofluoric acid burns (chelates fluoride ion)<br>
        ‚Ä¢ Citrate toxicity (massive blood transfusion)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Hypercalcemia<br>
        ‚Ä¢ Digoxin toxicity (relative - may worsen arrhythmias)<br>
        ‚Ä¢ Ventricular fibrillation (if from hyperkalemia, treat hyperkalemia first)<br>
        ‚Ä¢ Renal calculi (relative)<br>
        ‚Ä¢ Sarcoidosis (relative - may cause hypercalcemia)<br>
        ‚Ä¢ Known hypersensitivity
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="calcium-green">Hyperkalemia:</strong> 10 mL of 10% calcium gluconate (1g) IV over 5-10 minutes<br>
        ‚Ä¢ <strong class="calcium-green">Repeat:</strong> May repeat in 5-10 minutes if ECG changes persist<br>
        ‚Ä¢ <strong class="calcium-green">Hypocalcemia:</strong> 1-2g IV over 10-20 minutes, then infusion if needed<br>
        ‚Ä¢ <strong class="calcium-green">Infusion:</strong> 2g in 1L D5W/NS at 0.5-1.5 mL/kg/hr (0.5-1.5 mg/kg/hr elemental Ca)<br>
        ‚Ä¢ <strong class="calcium-green">Hydrofluoric acid burns:</strong> 10% gel topically OR intra-arterial infusion
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="calcium-green">Hyperkalemia:</strong> 0.5-1 mL/kg of 10% calcium gluconate IV over 5-10 min (max 10 mL)<br>
        ‚Ä¢ <strong class="calcium-green">Hypocalcemia:</strong> 200-500 mg/kg/day IV divided Q6-8H<br>
        ‚Ä¢ <strong class="calcium-green">Neonates:</strong> 200 mg/kg IV over 10-30 minutes<br>
        ‚Ä¢ <strong class="calcium-green">Maintenance:</strong> 200-400 mg/kg/day IV/PO divided Q6-8H
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="calcium-green">Routes:</strong> IV (preferred), intra-arterial (for HF burns), topical, PO<br>
        ‚Ä¢ <strong class="calcium-green">Preparation:</strong> 10% solution = 100 mg/mL (10 mg/mL elemental calcium)<br>
        ‚Ä¢ For IV: Give slowly (max 1-2 mL/min or 100-200 mg/min)<br>
        ‚Ä¢ Peripheral IV acceptable (less irritating than chloride)<br>
        ‚Ä¢ Incompatible with many drugs: bicarb, phosphates, ceftriaxone<br>
        ‚Ä¢ Warm to room temperature before administration (crystallizes when cold)
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Flushing, warmth sensation<br>
        ‚Ä¢ Nausea, vomiting<br>
        ‚Ä¢ Sweating<br>
        ‚Ä¢ Headache, dizziness<br>
        ‚Ä¢ Metallic taste<br>
        ‚Ä¢ Injection site pain (less than chloride)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Bradycardia, heart block (with rapid administration)<br>
        ‚Ä¢ Hypotension<br>
        ‚Ä¢ Hypercalcemia (with overdose)<br>
        ‚Ä¢ Tissue necrosis with extravasation<br>
        ‚Ä¢ Renal calculi (chronic use)<br>
        ‚Ä¢ Digitalis toxicity exacerbation (in patients on digoxin)<br>
        ‚Ä¢ Milk-alkali syndrome (with chronic oral use + alkali)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="calcium-green">Digoxin:</strong> Increased arrhythmias (monitor ECG closely)<br>
        ‚Ä¢ <strong class="calcium-green">Calcium channel blockers:</strong> Antagonizes effect<br>
        ‚Ä¢ <strong class="calcium-green">Tetracyclines, fluoroquinolones:</strong> Decreased absorption if given orally<br>
        ‚Ä¢ <strong class="calcium-green">Thiazide diuretics:</strong> Hypercalcemia risk<br>
        ‚Ä¢ <strong class="calcium-green">Sodium polystyrene sulfonate:</strong> May cause metabolic alkalosis<br>
        ‚Ä¢ <strong class="calcium-green">Ceftriaxone:</strong> Incompatible - forms precipitates in urine/gallbladder
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="calcium-green">For hyperkalemia:</strong> Works in 1-3 minutes, lasts 30-60 minutes<br>
        ‚Ä¢ <strong class="calcium-green">Does NOT lower K‚Å∫</strong> - only cardiac protection. Must follow with K‚Å∫-lowering treatments<br>
        ‚Ä¢ <strong class="calcium-green">Gluconate vs chloride:</strong> Gluconate preferred for peripheral IV (less irritating)<br>
        ‚Ä¢ <strong class="calcium-green">Elemental calcium:</strong> 1g calcium gluconate = 90mg elemental Ca (vs 270mg in chloride)<br>
        ‚Ä¢ <strong class="calcium-green">Incompatible with bicarb</strong> - forms calcium carbonate precipitate<br>
        ‚Ä¢ <strong class="calcium-green">Digoxin patients:</strong> Use with extreme caution, give slowly, monitor ECG continuously<br>
        ‚Ä¢ <strong class="calcium-green">Repeat dosing:</strong> May need repeat doses every 30-60 minutes if K‚Å∫ still high<br>
        ‚Ä¢ <strong class="calcium-green">Storage:</strong> May crystallize when cold - warm to dissolve before use
    </div>
</div>

<!-- CHAPTER 5: DRUG 4 - CALCIUM CHLORIDE -->
<div class="page-break"></div>
<h2><span class="chapter-number">5</span> Core Drug 4: Calcium Chloride</h2>

<div class="drug-template">
    <h4>CALCIUM CHLORIDE - HIGHER POTENCY, MORE IRRITATING</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Electrolyte supplement, cation
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Provides ionized calcium ‚Üí stabilizes cardiac cell membranes<br>
        ‚Ä¢ Increases myocardial contractility (positive inotrope)<br>
        ‚Ä¢ Essential for neuromuscular function, coagulation, enzyme systems<br>
        ‚Ä¢ Higher elemental calcium content than gluconate (27% vs 9%)<br>
        ‚Ä¢ Acidifying effect (chloride ion) - may worsen acidosis
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Hyperkalemia with ECG changes (when central line available)<br>
        ‚Ä¢ Hypocalcemia (especially with rapid correction needed)<br>
        ‚Ä¢ Calcium channel blocker overdose (severe hypotension)<br>
        ‚Ä¢ Magnesium sulfate overdose/toxicity<br>
        ‚Ä¢ Beta-blocker overdose (with severe hypotension)<br>
        ‚Ä¢ CPR (controversial - not in ACLS guidelines except specific situations)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Hypercalcemia<br>
        ‚Ä¢ Digoxin toxicity (absolute contraindication - ventricular fibrillation risk)<br>
        ‚Ä¢ Ventricular fibrillation (unless from hyperkalemia)<br>
        ‚Ä¢ Renal failure with hyperphosphatemia (metastatic calcification risk)<br>
        ‚Ä¢ Peripheral IV (relative - causes severe tissue necrosis if extravasates)<br>
        ‚Ä¢ Known hypersensitivity
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="calcium-green">Hyperkalemia:</strong> 5-10 mL of 10% calcium chloride (500-1000 mg) IV over 5-10 min<br>
        ‚Ä¢ <strong class="calcium-green">Hypocalcemia:</strong> 5-10 mL of 10% solution IV over 10-20 minutes<br>
        ‚Ä¢ <strong class="calcium-green">Calcium channel blocker OD:</strong> 10-20 mL of 10% over 10 min, repeat as needed<br>
        ‚Ä¢ <strong class="calcium-green">Infusion:</strong> 1-2 mg/kg/hr elemental calcium (3.7-7.4 mg/kg/hr calcium chloride)<br>
        ‚Ä¢ <strong class="calcium-green">CPR (if indicated):</strong> 5-10 mL of 10% IV (historical use)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="calcium-green">Hyperkalemia:</strong> 0.2-0.5 mL/kg of 10% calcium chloride IV over 5-10 min<br>
        ‚Ä¢ <strong class="calcium-green">Hypocalcemia:</strong> 10-20 mg/kg (0.1-0.2 mL/kg of 10%) IV over 10-20 min<br>
        ‚Ä¢ <strong class="calcium-green">Neonates:</strong> 20 mg/kg IV over 10-30 minutes<br>
        ‚Ä¢ <strong class="calcium-green">MAX peripheral concentration:</strong> 20 mg/mL (2%) - dilute for peripheral use
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="calcium-green">Route:</strong> IV through CENTRAL LINE ONLY (highly vesicant)<br>
        ‚Ä¢ <strong class="calcium-green">Preparation:</strong> 10% solution = 100 mg/mL (27 mg/mL elemental calcium)<br>
        ‚Ä¢ For IV: Give slowly (max 0.7-1.4 mL/min or 70-140 mg/min)<br>
        ‚Ä¢ <strong class="calcium-green">NEVER give peripherally</strong> unless absolutely necessary and well diluted<br>
        ‚Ä¢ Incompatible with bicarb, phosphates, ceftriaxone, amphotericin B<br>
        ‚Ä¢ Contains aluminum (up to 4.5 mcg/mL) - concern for neonates/renal failure
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Severe burning at injection site (even with central line)<br>
        ‚Ä¢ Flushing, warmth sensation<br>
        ‚Ä¢ Nausea, vomiting<br>
        ‚Ä¢ Headache, dizziness<br>
        ‚Ä¢ Metallic taste<br>
        ‚Ä¢ Hypotension (paradoxical, with rapid administration)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Tissue necrosis, sloughing with extravasation (SERIOUS)<br>
        ‚Ä¢ Hypercalcemia (with overdose) - stones, bones, groans, psychiatric overtones<br>
        ‚Ä¢ Bradycardia, heart block (rapid administration)<br>
        ‚Ä¢ Digoxin toxicity exacerbation (ventricular fibrillation)<br>
        ‚Ä¢ Metabolic acidosis (chloride load)<br>
        ‚Ä¢ Aluminum toxicity (with prolonged use in renal failure)<br>
        ‚Ä¢ Phlebitis, thrombosis
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="calcium-green">Digoxin:</strong> ABSOLUTE contraindication in toxicity (fatal arrhythmias)<br>
        ‚Ä¢ <strong class="calcium-green">Calcium channel blockers:</strong> Antagonizes effect (therapeutic in overdose)<br>
        ‚Ä¢ <strong class="calcium-green">Neuromuscular blockers:</strong> Potentiates effects<br>
        ‚Ä¢ <strong class="calcium-green">Tetracyclines, fluoroquinolones:</strong> Decreased absorption<br>
        ‚Ä¢ <strong class="calcium-green">Sodium bicarbonate:</strong> Incompatible - precipitates<br>
        ‚Ä¢ <strong class="calcium-green">Ceftriaxone:</strong> Incompatible - risk of concretions
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="calcium-green">CENTRAL LINE ONLY</strong> - causes severe tissue necrosis if extravasates<br>
        ‚Ä¢ <strong class="calcium-green">3x more elemental calcium</strong> than gluconate: 1g chloride = 270mg Ca¬≤‚Å∫ vs 90mg in gluconate<br>
        ‚Ä¢ <strong class="calcium-green">For hyperkalemia:</strong> Works faster than gluconate (higher ionized calcium)<br>
        ‚Ä¢ <strong class="calcium-green">Digoxin patients:</strong> CONTRAINDICATED if digoxin toxicity suspected<br>
        ‚Ä¢ <strong class="calcium-green">Calcium channel blocker OD:</strong> High-dose therapy (up to 10g over hours)<br>
        ‚Ä¢ <strong class="calcium-green">Extravasation treatment:</strong> Stop infusion, aspirate, hyaluronidase injection<br>
        ‚Ä¢ <strong class="calcium-green">ACLS:</strong> Not recommended in routine CPR (limited to hyperK‚Å∫, hypocalcemia, CCB OD)<br>
        ‚Ä¢ <strong class="calcium-green">Storage:</strong> Store at room temperature, crystals form when cold
    </div>
</div>

<div class="clinical-pearl">
    <strong>üß† CALCIUM GLUCONATE vs CHLORIDE:</strong><br>
    ‚Ä¢ <strong>Calcium Gluconate:</strong> 9% elemental Ca, peripheral IV safe, first choice for hyperkalemia<br>
    ‚Ä¢ <strong>Calcium Chloride:</strong> 27% elemental Ca, central line only, for critical cases/CCB overdose<br>
    ‚Ä¢ <em>1g Calcium Chloride = 3g Calcium Gluconate in elemental calcium content</em>
</div>

<!-- CHAPTER 6: DRUG 5 - POTASSIUM CHLORIDE (EMERGENCY USE) -->
<div class="page-break"></div>
<h2><span class="chapter-number">6</span> Core Drug 5: Potassium Chloride (Emergency Use)</h2>

<div class="drug-template">
    <h4>POTASSIUM CHLORIDE - HIGH-RISK ELECTROLYTE REPLACEMENT</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Electrolyte supplement, cation
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Principal intracellular cation (98% of total body K‚Å∫ is intracellular)<br>
        ‚Ä¢ Essential for resting membrane potential, cardiac rhythm, neuromuscular function<br>
        ‚Ä¢ Activates Na‚Å∫/K‚Å∫ ATPase (with insulin, beta-agonists)<br>
        ‚Ä¢ Renal excretion regulated by aldosterone, distal tubular flow, pH<br>
        ‚Ä¢ Chloride salt helps correct metabolic alkalosis (chloride-responsive)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Hypokalemia (K‚Å∫ <3.5 mEq/L)<br>
        ‚Ä¢ Hypokalemia with ECG changes (U waves, flattened T waves)<br>
        ‚Ä¢ Digitalis toxicity (hypokalemia potentiates toxicity)<br>
        ‚Ä¢ Periodic paralysis (hypokalemic type)<br>
        ‚Ä¢ Diabetic ketoacidosis (K‚Å∫ shifts out during treatment)<br>
        ‚Ä¢ Metabolic alkalosis (chloride-responsive)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ <strong class="potassium-red">Hyperkalemia</strong> (obvious)<br>
        ‚Ä¢ Renal failure with oliguria/anuria (relative)<br>
        ‚Ä¢ Addison's disease (relative - impaired excretion)<br>
        ‚Ä¢ Severe tissue trauma (crush injury - K‚Å∫ release)<br>
        ‚Ä¢ Digitalis toxicity with AV block (relative)<br>
        ‚Ä¢ <strong class="potassium-red">NEVER IV push</strong> (cardiac arrest)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="potassium-red">Mild hypokalemia (K‚Å∫ 3.0-3.5):</strong> 10-20 mEq PO Q6-8H<br>
        ‚Ä¢ <strong class="potassium-red">Moderate (K‚Å∫ 2.5-3.0):</strong> 20-40 mEq IV over 2-4 hours<br>
        ‚Ä¢ <strong class="potassium-red">Severe (K‚Å∫ <2.5 or ECG changes):</strong> 40-60 mEq IV over 4-6 hours<br>
        ‚Ä¢ <strong class="potassium-red">Max peripheral concentration:</strong> 40 mEq/L (or 10 mEq/100 mL)<br>
        ‚Ä¢ <strong class="potassium-red">Max central concentration:</strong> 80-100 mEq/L (depends on institution)<br>
        ‚Ä¢ <strong class="potassium-red">Max infusion rate:</strong> 10-20 mEq/hr (up to 40 mEq/hr in ICU with cardiac monitoring)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="potassium-red">Mild hypokalemia:</strong> 1-2 mEq/kg/day PO divided Q6-8H<br>
        ‚Ä¢ <strong class="potassium-red">IV replacement:</strong> 0.5-1 mEq/kg over 1-2 hours (max 40 mEq)<br>
        ‚Ä¢ <strong class="potassium-red">Maintenance:</strong> 2-4 mEq/kg/day<br>
        ‚Ä¢ <strong class="potassium-red">Neonates:</strong> 0.5-1 mEq/kg over 1-2 hours (max 10 mEq)<br>
        ‚Ä¢ <strong class="potassium-red">Max rate:</strong> 0.5 mEq/kg/hr (with cardiac monitoring)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="potassium-red">Routes:</strong> IV infusion (preferred for emergencies), PO, NG<br>
        ‚Ä¢ <strong class="potassium-red">Preparation:</strong> 2 mEq/mL (concentrated) or pre-mixed bags (10, 20, 40 mEq/L)<br>
        ‚Ä¢ <strong class="potassium-red">NEVER IV push or bolus</strong> - cardiac arrest risk<br>
        ‚Ä¢ Peripheral IV: Max 40 mEq/L (or 10 mEq/100mL) to avoid phlebitis<br>
        ‚Ä¢ Central line: Higher concentrations possible (follow institutional policy)<br>
        ‚Ä¢ Use infusion pump with dose limit set<br>
        ‚Ä¢ Incompatible with many drugs: amphotericin, ceftriaxone, fat emulsions
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Nausea, vomiting, abdominal pain (especially PO)<br>
        ‚Ä¢ Phlebitis, pain at IV site<br>
        ‚Ä¢ Diarrhea (PO preparation)<br>
        ‚Ä¢ Metallic taste<br>
        ‚Ä¢ Sensation of warmth with IV
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Hyperkalemia ‚Üí cardiac arrest (most serious)<br>
        ‚Ä¢ Tissue necrosis with extravasation (high concentrations)<br>
        ‚Ä¢ Small bowel lesions/ulceration (enteric-coated tablets)<br>
        ‚Ä¢ Metabolic acidosis (with chloride salt in renal impairment)<br>
        ‚Ä¢ Phlebitis, thrombosis<br>
        ‚Ä¢ Arrhythmias (both hypo- and hyperkalemia)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="potassium-red">ACE inhibitors, ARBs, NSAIDs, potassium-sparing diuretics:</strong> Hyperkalemia risk<br>
        ‚Ä¢ <strong class="potassium-red">Digoxin:</strong> Hypokalemia increases toxicity; hyperkalemia decreases effect<br>
        ‚Ä¢ <strong class="potassium-red">Beta-agonists:</strong> Lower K‚Å∫ (intracellular shift)<br>
        ‚Ä¢ <strong class="potassium-red">Insulin:</strong> Lowers K‚Å∫ (intracellular shift)<br>
        ‚Ä¢ <strong class="potassium-red">Loop/thiazide diuretics:</strong> Increase K‚Å∫ loss<br>
        ‚Ä¢ <strong class="potassium-red">Sodium polystyrene sulfonate:</strong> Lowers K‚Å∫
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="potassium-red">"NEVER IV PUSH"</strong> - causes immediate hyperkalemia, cardiac arrest<br>
        ‚Ä¢ <strong class="potassium-red">ECG monitoring</strong> required for rates >10 mEq/hr or K‚Å∫ <2.5 mEq/L<br>
        ‚Ä¢ <strong class="potassium-red">Magnesium matters:</strong> Correct hypomagnesemia first (renal wasting of K‚Å∫)<br>
        ‚Ä¢ <strong class="potassium-red">DKA:</strong> K‚Å∫ often high initially but total body deficit - add to fluids when K‚Å∫ <5.5<br>
        ‚Ä¢ <strong class="potassium-red">Recheck K‚Å∫</strong> 2-4 hours after starting replacement<br>
        ‚Ä¢ <strong class="potassium-red">Chloride vs other salts:</strong> Chloride for metabolic alkalosis; acetate/phosphate for acidosis<br>
        ‚Ä¢ <strong class="potassium-red">Extravasation:</strong> Hyaluronidase injection for tissue salvage<br>
        ‚Ä¢ <strong class="potassium-red">Oral preferred</strong> when possible - safer, stimulates colonic K‚Å∫ secretion
    </div>
</div>

<!-- CHAPTER 7: DRUG 6 - SODIUM BICARBONATE -->
<div class="page-break"></div>
<h2><span class="chapter-number">7</span> Core Drug 6: Sodium Bicarbonate</h2>

<div class="drug-template">
    <h4>SODIUM BICARBONATE - ALKALINIZING AGENT FOR ACIDOSIS</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Alkalinizing agent, buffer
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ HCO‚ÇÉ‚Åª + H‚Å∫ ‚Üí H‚ÇÇCO‚ÇÉ ‚Üí CO‚ÇÇ + H‚ÇÇO (requires adequate ventilation)<br>
        ‚Ä¢ Raises blood pH by increasing bicarbonate concentration<br>
        ‚Ä¢ Alkalizes urine ‚Üí enhances elimination of weak acids (aspirin, phenobarbital)<br>
        ‚Ä¢ Hypertonic solution (8.4% = 2000 mOsm/L) ‚Üí fluid shift, Na‚Å∫ load<br>
        ‚Ä¢ May improve cardiac contractility in severe acidosis (pH <7.1)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Severe metabolic acidosis (pH <7.1, bicarbonate <8 mEq/L)<br>
        ‚Ä¢ Tricyclic antidepressant overdose (QRS >100 ms)<br>
        ‚Ä¢ Aspirin overdose (alkalinize urine to enhance elimination)<br>
        ‚Ä¢ Hyperkalemia (adjunct - drives K‚Å∫ into cells)<br>
        ‚Ä¢ Renal tubular acidosis (distal type)<br>
        ‚Ä¢ Cardiac arrest (controversial - limited to specific situations)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Metabolic/respiratory alkalosis<br>
        ‚Ä¢ Hypocalcemia (worsens tetany)<br>
        ‚Ä¢ Hypernatremia (contains Na‚Å∫)<br>
        ‚Ä¢ Volume overload, heart failure (Na‚Å∫ load)<br>
        ‚Ä¢ Hypokalemia (worsens with intracellular shift)<br>
        ‚Ä¢ Unknown ingestion/acidosis (may worsen some toxic alcohols)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="bicarbonate-purple">Severe acidosis:</strong> 1-2 mEq/kg IV bolus (50-100 mEq), then infusion as needed<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Infusion:</strong> Add 150 mEq (3 amps 50 mEq each) to 1L D5W, titrate to pH<br>
        ‚Ä¢ <strong class="bicarbonate-purple">TCA overdose (QRS >100 ms):</strong> 1-2 mEq/kg bolus, repeat to narrow QRS<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Aspirin overdose:</strong> Target urine pH 7.5-8.0, serum pH 7.5-7.55<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Hyperkalemia:</strong> 50 mEq IV over 5 minutes (works in 15-30 minutes)<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Formula for deficit:</strong> HCO‚ÇÉ‚Åª deficit (mEq) = 0.5 √ó weight (kg) √ó (24 - measured HCO‚ÇÉ‚Åª)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="bicarbonate-purple">Acidosis:</strong> 1-2 mEq/kg IV bolus over 30-60 minutes<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Infusion:</strong> 2-5 mEq/kg/day IV divided<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Neonates:</strong> 1-2 mEq/kg IV over 30 minutes (4.2% solution preferred)<br>
        ‚Ä¢ <strong class="bicarbonate-purple">CPR:</strong> 1 mEq/kg IV (only if prolonged arrest, hyperkalemia, TCA overdose)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="bicarbonate-purple">Routes:</strong> IV (preferred), PO (for chronic acidosis)<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Concentrations:</strong> 4.2% (0.5 mEq/mL), 8.4% (1 mEq/mL)<br>
        ‚Ä¢ <strong class="bicarbonate-purple">For IV bolus:</strong> Usually 8.4% (1 mEq/mL) - give over 5-30 minutes<br>
        ‚Ä¢ <strong class="bicarbonate-purple">For infusion:</strong> Dilute to isotonic (1.4% = 0.167 mEq/mL)<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Incompatible with:</strong> Calcium, catecholamines, many antibiotics<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Use within 24 hours</strong> of opening - absorbs CO‚ÇÇ from air
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Metabolic alkalosis (overcorrection)<br>
        ‚Ä¢ Hypernatremia (Na‚Å∫ load)<br>
        ‚Ä¢ Fluid overload (hypertonic solution)<br>
        ‚Ä¢ Hypokalemia (intracellular shift)<br>
        ‚Ä¢ Hypocalcemia (increased protein binding)<br>
        ‚Ä¢ Local irritation (hypertonic)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Paradoxical intracellular acidosis (excess CO‚ÇÇ production)<br>
        ‚Ä¢ Cerebral edema (rapid correction in chronic acidosis)<br>
        ‚Ä¢ Tetany, seizures (hypocalcemia)<br>
        ‚Ä¢ Reduced tissue oxygenation (left shift of oxyhemoglobin curve)<br>
        ‚Ä¢ Milk-alkali syndrome (chronic use)<br>
        ‚Ä¢ Hyperosmolality, hypertonic dehydration
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="bicarbonate-purple">Aspirin, phenobarbital:</strong> Increased renal elimination (alkaline urine)<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Quinidine, flecainide:</strong> Increased renal reabsorption (alkaline urine)<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Lithium:</strong> Increased renal excretion<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Ketoconazole, itraconazole:</strong> Decreased absorption (reduced gastric acidity)<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Calcium, magnesium:</strong> Incompatible - precipitates<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Catecholamines:</strong> Incompatible - inactivates
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="bicarbonate-purple">"pH <7.1 rule":</strong> Consider only when pH <7.1 (except specific overdoses)<br>
        ‚Ä¢ <strong class="bicarbonate-purple">TCA overdose:</strong> Give to narrow QRS >100 ms, not based on pH<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Aspirin overdose:</strong> Urine alkalinization more important than serum correction<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Paradoxical acidosis:</strong> Ensure adequate ventilation to blow off CO‚ÇÇ<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Hyperkalemia:</strong> Works in 15-30 minutes, lasts 1-2 hours<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Half-correction:</strong> Aim to raise bicarbonate to 12-14 mEq/L, not to normal<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Chronic acidosis:</strong> Correct slowly (over days) to avoid cerebral edema<br>
        ‚Ä¢ <strong class="bicarbonate-purple">Storage:</strong> Keep vial tightly closed - absorbs CO‚ÇÇ and loses potency
    </div>
</div>

<!-- CHAPTER 8: DRUG 7 - MAGNESIUM SULFATE (METABOLIC) -->
<div class="page-break"></div>
<h2><span class="chapter-number">8</span> Core Drug 7: Magnesium Sulfate (Metabolic Focus)</h2>

<div class="drug-template">
    <h4>MAGNESIUM SULFATE - FOR HYPOMAGNESEMIA & REFRACTORY ARRHYTHMIAS</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Electrolyte supplement, cation
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Essential cofactor for Na‚Å∫/K‚Å∫ ATPase ‚Üí affects K‚Å∫ handling<br>
        ‚Ä¢ Natural calcium channel blocker ‚Üí vasodilation, bronchodilation<br>
        ‚Ä¢ Membrane stabilizer ‚Üí antiarrhythmic properties<br>
        ‚Ä¢ Neuromuscular blocker (presynaptic inhibition of acetylcholine)<br>
        ‚Ä¢ Cofactor for many enzymatic reactions (ATP metabolism)<br>
        ‚Ä¢ Stimulates PTH secretion (important for calcium regulation)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Hypomagnesemia (especially with seizures, arrhythmias)<br>
        ‚Ä¢ Torsades de pointes (first-line treatment)<br>
        ‚Ä¢ Digitalis-induced arrhythmias<br>
        ‚Ä¢ Severe asthma (covered in Module 3)<br>
        ‚Ä¢ Eclampsia/pre-eclampsia (different dosing)<br>
        ‚Ä¢ Refractory ventricular fibrillation/tachycardia
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Hypermagnesemia<br>
        ‚Ä¢ Heart block (without pacemaker)<br>
        ‚Ä¢ Myasthenia gravis (worsens weakness)<br>
        ‚Ä¢ Severe renal impairment (CrCl <30 mL/min)<br>
        ‚Ä¢ Concurrent use of neuromuscular blockers<br>
        ‚Ä¢ Known hypersensitivity
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="magnesium-teal">Hypomagnesemia (severe):</strong> 2-4 g IV over 10-30 minutes, then 1-2 g/hr infusion<br>
        ‚Ä¢ <strong class="magnesium-teal">Hypomagnesemia (mild):</strong> 1 g IV over 1 hour, repeat as needed<br>
        ‚Ä¢ <strong class="magnesium-teal">Torsades de pointes:</strong> 1-2 g IV over 5-20 minutes<br>
        ‚Ä¢ <strong class="magnesium-teal">Refractory VF/VT:</strong> 1-2 g IV push during CPR<br>
        ‚Ä¢ <strong class="magnesium-teal">Digitalis toxicity:</strong> 1-2 g IV over 5-10 minutes<br>
        ‚Ä¢ <strong class="magnesium-teal">Maintenance:</strong> 0.5-1 g/hr for 24 hours, then 0.5-1 g Q6H
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="magnesium-teal">Hypomagnesemia:</strong> 25-50 mg/kg IV over 10-30 minutes (max 2 g)<br>
        ‚Ä¢ <strong class="magnesium-teal">Torsades:</strong> 25-50 mg/kg IV over 10-20 minutes (max 2 g)<br>
        ‚Ä¢ <strong class="magnesium-teal">Refractory VF:</strong> 25-50 mg/kg IV push (max 2 g)<br>
        ‚Ä¢ <strong class="magnesium-teal">Maintenance:</strong> 30-60 mg/kg/day divided Q4-6H<br>
        ‚Ä¢ <strong class="magnesium-teal">Neonates:</strong> 25-50 mg/kg IV over 1-2 hours
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="magnesium-teal">Routes:</strong> IV (preferred), IM (painful), PO (poorly absorbed)<br>
        ‚Ä¢ <strong class="magnesium-teal">Concentrations:</strong> 1 g/2 mL (50%), 2 g/10 mL (20%), 4 g/8 mL (50%)<br>
        ‚Ä¢ <strong class="magnesium-teal">For IV infusion:</strong> Dilute to ‚â§20% (200 mg/mL) to reduce vein irritation<br>
        ‚Ä¢ <strong class="magnesium-teal">IM:</strong> Use 50% solution, deep injection, massage site<br>
        ‚Ä¢ <strong class="magnesium-teal">Incompatible with:</strong> Calcium, bicarb, fat emulsions, many antibiotics<br>
        ‚Ä¢ <strong class="magnesium-teal">Hypertonic:</strong> 50% solution = 4000 mOsm/L - dilute for peripheral IV
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Flushing, warmth sensation<br>
        ‚Ä¢ Nausea, vomiting<br>
        ‚Ä¢ Headache, dizziness<br>
        ‚Ä¢ Muscle weakness, lethargy<br>
        ‚Ä¢ Hypotension (vasodilation)<br>
        ‚Ä¢ Injection site pain/phlebitis
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Respiratory depression/arrest (>4-5 mEq/L)<br>
        ‚Ä¢ Heart block, cardiac arrest (>10-15 mEq/L)<br>
        ‚Ä¢ Loss of deep tendon reflexes (first sign of toxicity)<br>
        ‚Ä¢ Hypotension (especially with rapid infusion)<br>
        ‚Ä¢ Hypocalcemia (displaces calcium)<br>
        ‚Ä¢ Hypermagnesemia in renal failure
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="magnesium-teal">Neuromuscular blockers:</strong> Potentiates effect<br>
        ‚Ä¢ <strong class="magnesium-teal">Calcium channel blockers:</strong> Additive hypotension<br>
        ‚Ä¢ <strong class="magnesium-teal">Digoxin:</strong> May worsen heart block<br>
        ‚Ä¢ <strong class="magnesium-teal">Aminoglycosides, cisplatin:</strong> Increased renal Mg loss<br>
        ‚Ä¢ <strong class="magnesium-teal">Calcium:</strong> Antagonizes effects (antidote)<br>
        ‚Ä¢ <strong class="magnesium-teal">Tetracyclines, fluoroquinolones:</strong> Decreased absorption (PO)
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="magnesium-teal">"Check Mg in all hypokalemia"</strong> - Mg needed for renal K‚Å∫ conservation<br>
        ‚Ä¢ <strong class="magnesium-teal">For torsades:</strong> Give regardless of magnesium level<br>
        ‚Ä¢ <strong class="magnesium-teal">Monitor reflexes</strong> during infusion - loss indicates toxicity<br>
        ‚Ä¢ <strong class="magnesium-teal">Antidote:</strong> Calcium gluconate/chloride 1 g IV for toxicity<br>
        ‚Ä¢ <strong class="magnesium-teal">Normal level:</strong> 1.5-2.5 mg/dL (0.6-1 mmol/L)<br>
        ‚Ä¢ <strong class="magnesium-teal">Therapeutic for arrhythmias:</strong> 4-6 mg/dL (1.6-2.4 mmol/L)<br>
        ‚Ä¢ <strong class="magnesium-teal">Renal excretion:</strong> Reduce dose/frequency in renal impairment<br>
        ‚Ä¢ <strong class="magnesium-teal">Refeeding syndrome:</strong> Monitor Mg closely during nutritional rehabilitation
    </div>
</div>

<!-- CHAPTER 9: HYPERKALEMIA MANAGEMENT PROTOCOL -->
<div class="page-break"></div>
<h2><span class="chapter-number">9</span> Hyperkalemia Management Protocol</h2>

<div class="hyperkalemia-box">
    <strong>‚ö†Ô∏è HYPERKALEMIA EMERGENCY (K‚Å∫ >6.5 OR ECG CHANGES):</strong><br>
    <br>
    <strong>STEP 1: ASSESS & STABILIZE (0-5 MINUTES)</strong><br>
    ‚Ä¢ ECG immediately (peaked T waves ‚Üí widened QRS ‚Üí sine wave ‚Üí VF)<br>
    ‚Ä¢ IV access, cardiac monitor<br>
    ‚Ä¢ Stop K‚Å∫ supplements, K‚Å∫-sparing drugs, ACE/ARBs<br>
    <br>
    <strong>STEP 2: CARDIOPROTECTION (IMMEDIATE)</strong><br>
    ‚Ä¢ <strong class="calcium-green">Calcium gluconate 10% 10 mL IV over 5-10 min</strong><br>
    ‚Ä¢ Repeat in 5-10 min if ECG changes persist<br>
    ‚Ä¢ Works in 1-3 minutes, lasts 30-60 minutes<br>
    ‚Ä¢ <em>Note: Does NOT lower K‚Å∫, only protects heart</em><br>
    <br>
    <strong>STEP 3: SHIFT K‚Å∫ INTO CELLS (MINUTES TO HOURS)</strong><br>
    ‚Ä¢ Choose one or more:<br>
    &nbsp;&nbsp;‚Ä¢ <strong class="insulin-blue">Regular insulin 10 units IV + 25g dextrose (50 mL 50%)</strong> (works in 15-30 min)<br>
    &nbsp;&nbsp;‚Ä¢ <strong class="bicarbonate-purple">NaHCO‚ÇÉ 50 mEq IV over 5 min</strong> (if acidotic, works in 15-30 min)<br>
    &nbsp;&nbsp;‚Ä¢ <strong class="glucose-orange">Salbutamol nebulizer 10-20 mg</strong> (works in 30 min, adjunct)<br>
    <br>
    <strong>STEP 4: REMOVE K‚Å∫ FROM BODY (HOURS TO DAYS)</strong><br>
    ‚Ä¢ <strong>Loop diuretic:</strong> Furosemide 40-80 mg IV (if renal function adequate)<br>
    ‚Ä¢ <strong>Cation exchange resin:</strong> Sodium polystyrene sulfonate 15-30g PO/PR<br>
    ‚Ä¢ <strong>Dialysis:</strong> For refractory cases, renal failure, life-threatening<br>
    <br>
    <strong>STEP 5: MONITOR & PREVENT RECURRENCE</strong><br>
    ‚Ä¢ Check K‚Å∫ 1-2 hours after treatment<br>
    ‚Ä¢ Continuous cardiac monitoring<br>
    ‚Ä¢ Treat underlying cause (AKI, rhabdo, adrenal insufficiency, etc.)
</div>

<h3>9.1 Hyperkalemia ECG Progression</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>K‚Å∫ Level (mEq/L)</th>
            <th>ECG Changes</th>
            <th>Treatment Urgency</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>5.5-6.5</strong></td>
            <td>Peaked T waves (tenting)</td>
            <td>Urgent (shift and remove)</td>
        </tr>
        <tr>
            <td><strong>6.5-7.5</strong></td>
            <td>Loss of P waves, widened QRS</td>
            <td>Emergency (calcium + shift)</td>
        </tr>
        <tr>
            <td><strong>7.5-8.5</strong></td>
            <td>Sine wave pattern</td>
            <td>Immediate (calcium first)</td>
        </tr>
        <tr>
            <td><strong>>8.5</strong></td>
            <td>Ventricular fibrillation, asystole</td>
            <td>CPR + immediate calcium</td>
        </tr>
    </tbody>
</table>

<!-- CHAPTER 10: DKA MANAGEMENT CALCULATIONS -->
<div class="page-break"></div>
<h2><span class="chapter-number">10</span> DKA Calculations & Monitoring</h2>

<h3>10.1 Essential DKA Calculations</h3>

<div class="calculation-box">
    <strong>üìä ANION GAP:</strong> Na‚Å∫ - (Cl‚Åª + HCO‚ÇÉ‚Åª) = Normal 8-12 mEq/L<br>
    ‚Ä¢ Elevated in DKA (usually >20)<br>
    ‚Ä¢ Monitor to assess treatment response<br>
    <br>
    <strong>üìä EFFECTIVE SERUM OSMOLALITY:</strong> 2 √ó Na‚Å∫ + glucose (mmol/L) + urea (mmol/L)<br>
    ‚Ä¢ Or: 2 √ó Na‚Å∫ + glucose/18 + BUN/2.8 (if mg/dL)<br>
    ‚Ä¢ Normal: 275-295 mOsm/kg<br>
    ‚Ä¢ In HHS: Often >320 mOsm/kg<br>
    <br>
    <strong>üìä SODIUM CORRECTION FOR HYPERGLYCEMIA:</strong><br>
    Corrected Na‚Å∫ = Measured Na‚Å∫ + 0.024 √ó (glucose - 5.5) [if mmol/L]<br>
    Or: Corrected Na‚Å∫ = Measured Na‚Å∫ + 0.016 √ó (glucose - 100) [if mg/dL]<br>
    ‚Ä¢ Falling corrected Na‚Å∫ during treatment = cerebral edema risk<br>
    <br>
    <strong>üìä FLUID DEFICIT IN DKA:</strong> Usually 6-10% of body weight<br>
    ‚Ä¢ 70 kg patient: ~4.2-7.0 L deficit<br>
    ‚Ä¢ Replace over 24-48 hours<br>
    <br>
    <strong>üìä INSULIN INFUSION RATE:</strong> 0.1 units/kg/hr<br>
    ‚Ä¢ 70 kg patient: 7 units/hr = 7 mL/hr (if 1 unit/mL)<br>
    ‚Ä¢ Titrate to glucose drop of 2.8-4.2 mmol/L/hr (50-75 mg/dL/hr)
</div>

<h3>10.2 DKA Monitoring Schedule</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Parameter</th>
            <th>First 4 hours</th>
            <th>4-12 hours</th>
            <th>After 12 hours</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Blood glucose</strong></td>
            <td>Hourly</td>
            <td>Every 2 hours</td>
            <td>Every 4-6 hours</td>
        </tr>
        <tr>
            <td><strong>Electrolytes</strong></td>
            <td>Every 2 hours</td>
            <td>Every 4 hours</td>
            <td>Every 6-8 hours</td>
        </tr>
        <tr>
            <td><strong>VBG/ABG</strong></td>
            <td>Every 2 hours</td>
            <td>Every 4 hours</td>
            <td>Every 6-8 hours</td>
        </tr>
        <tr>
            <td><strong>Anion gap</strong></td>
            <td>Every 2 hours</td>
            <td>Every 4 hours</td>
            <td>Every 6-8 hours</td>
        </tr>
        <tr>
            <td><strong>Urine output</strong></td>
            <td>Hourly</td>
            <td>Every 2 hours</td>
            <td>Every 4 hours</td>
        </tr>
        <tr>
            <td><strong>Neurological obs</strong></td>
            <td>Every 30 min</td>
            <td>Hourly</td>
            <td>Every 2 hours</td>
        </tr>
    </tbody>
</table>

<!-- APPENDIX: QUICK REFERENCE GUIDES -->
<div class="page-break"></div>
<h2>Appendix: Quick Reference Guides</h2>

<h3>Metabolic Emergency Drug Comparison</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Drug</th>
            <th>Key Indication</th>
            <th>Onset</th>
            <th>Duration</th>
            <th>Critical Monitoring</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Dextrose 50%</strong></td>
            <td>Hypoglycemia</td>
            <td>1-3 min</td>
            <td>30-60 min</td>
            <td>Glucose 15 min after, K‚Å∫</td>
        </tr>
        <tr>
            <td><strong>Insulin regular</strong></td>
            <td>DKA/Hyperkalemia</td>
            <td>10-30 min</td>
            <td>4-6 hours</td>
            <td>Glucose hourly, K‚Å∫ q2-4h</td>
        </tr>
        <tr>
            <td><strong>Calcium gluconate</strong></td>
            <td>Hyperkalemia (cardiac)</td>
            <td>1-3 min</td>
            <td>30-60 min</td>
            <td>ECG during infusion</td>
        </tr>
        <tr>
            <td><strong>Calcium chloride</strong></td>
            <td>CCB overdose</td>
            <td>1-2 min</td>
            <td>30-60 min</td>
            <td>BP, ECG, central line only</td>
        </tr>
        <tr>
            <td><strong>KCl IV</strong></td>
            <td>Hypokalemia</td>
            <td>Variable</td>
            <td>Hours</td>
            <td>K‚Å∫ q2-4h, ECG if rapid</td>
        </tr>
        <tr>
            <td><strong>NaHCO‚ÇÉ</strong></td>
            <td>Severe acidosis/TCA OD</td>
            <td>5-30 min</td>
            <td>Hours</td>
            <td>pH, Na‚Å∫, K‚Å∫, Ca¬≤‚Å∫</td>
        </tr>
        <tr>
            <td><strong>MgSO‚ÇÑ</strong></td>
            <td>Torsades/Hypomagnesemia</td>
            <td>5-30 min</td>
            <td>Hours</td>
            <td>Reflexes, ECG, Mg level</td>
        </tr>
    </tbody>
</table>

<h3>Critical Electrolyte Levels (When to Treat)</h3>

<div class="metabolic-box">
    <strong>üî¥ CRITICAL VALUES REQUIRING IMMEDIATE TREATMENT:</strong><br>
    ‚Ä¢ <strong class="potassium-red">K‚Å∫ >6.5 mEq/L</strong> OR any K‚Å∫ with ECG changes<br>
    ‚Ä¢ <strong class="glucose-orange">Glucose <2.8 mmol/L (50 mg/dL)</strong> OR any symptomatic hypoglycemia<br>
    ‚Ä¢ <strong class="glucose-orange">Glucose >33.3 mmol/L (600 mg/dL)</strong> in HHS<br>
    ‚Ä¢ <strong class="bicarbonate-purple">pH <7.1</strong> (except respiratory acidosis)<br>
    ‚Ä¢ <strong class="calcium-green">Ionized Ca¬≤‚Å∫ <0.8 mmol/L</strong> OR symptomatic hypocalcemia<br>
    ‚Ä¢ <strong class="magnesium-teal">Mg¬≤‚Å∫ <0.5 mmol/L</strong> with seizures/arrhythmias<br>
    ‚Ä¢ <strong>Na‚Å∫ <120 or >160 mEq/L</strong> (correct slowly!)
</div>

<h3>Monitoring Parameters for Metabolic Drugs</h3>
<ul>
    <li><strong>Dextrose:</strong> Glucose 15 min after dose, potassium (insulin-mediated shift)</li>
    <li><strong>Insulin:</strong> Hourly glucose, potassium q2-4h, anion gap in DKA</li>
    <li><strong>Calcium:</strong> ECG during infusion, ionized calcium if available</li>
    <li><strong>Potassium:</strong> Serum K‚Å∫ q2-4h, ECG if >10 mEq/hr or K‚Å∫ <2.5</li>
    <li><strong>Bicarbonate:</strong> ABG/VBG 1-2h after dose, electrolytes (Na‚Å∫, K‚Å∫, Ca¬≤‚Å∫)</li>
    <li><strong>Magnesium:</strong> Deep tendon reflexes during infusion, Mg level 2h after load</li>
    <li><strong>General:</strong> Neurological observations, urine output, fluid balance</li>
</ul>

<div class="study-format">
    <h2><span class="emoji">üß†</span> DRUG TEMPLATE SUMMARY FOR MODULE 5</h2>
    <p><strong>All 7 drugs in this module follow the consistent 11-point format:</strong></p>
    <ol>
        <li><strong>Drug class</strong> - Pharmacological category</li>
        <li><strong>Mechanism of action</strong> - How it works at cellular/physiological level</li>
        <li><strong>Indications</strong> - Specific metabolic/electrolyte emergencies</li>
        <li><strong>Contraindications</strong> - Absolute and relative contraindications</li>
        <li><strong>Adult dose</strong> - Exact emergency dosing (critical calculations)</li>
        <li><strong>Pediatric dose</strong> - Weight-based calculations (special considerations)</li>
        <li><strong>Route & preparation</strong> - How to prepare and administer safely</li>
        <li><strong>Side effects</strong> - Common, expected effects</li>
        <li><strong>Adverse effects / ADR</strong> - Serious reactions and toxicity</li>
        <li><strong>Drug interactions</strong> - Important combinations to avoid/watch</li>
        <li><strong>Emergency pearls</strong> - Clinical tips, exam favorites, practical wisdom</li>
    </ol>
</div>

<div class="footer-note">
    <strong>¬© Emergency Medicine Education Team | Confidential Educational Material</strong><br>
    This document is for educational purposes only. Always follow local protocols and guidelines.<br>
    Medications and doses may vary by institution. Verify all information before clinical application.<br>
    Version 1.0 | Last updated: [Current Date] | Module 5 of 10
</div>
</body> </html>